ABSTRACT

Over the past decade, studies from a number of laboratories have highlighted the importance of proteolytic enzymes in the metabolism of protozoa, as well as in the pathogenesis of diseases caused by parasitic protozoa (McKerrow, 1989; North et al., 1990). Several of these enzymes are attractive targets for drug design. There are two approaches that can be taken as a first step in drug development. Traditionally, the enzyme of interest is identified and purified from the organism, and detailed biochemical analyses are carried out to determine inhibition profile and substrate specificity.